Globeflex Capital L P raised its position in Cambrex Corporation (NYSE:CBM) by 334.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,542 shares of the biotechnology company’s stock after buying an additional 16,582 shares during the period. Globeflex Capital L P owned approximately 0.07% of Cambrex Corporation worth $1,186,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Cambrex Corporation during the fourth quarter worth $14,500,000. Comerica Bank raised its position in shares of Cambrex Corporation by 21.0% in the fourth quarter. Comerica Bank now owns 54,967 shares of the biotechnology company’s stock worth $3,070,000 after buying an additional 9,528 shares in the last quarter. State Street Corp raised its position in shares of Cambrex Corporation by 5.3% in the fourth quarter. State Street Corp now owns 689,513 shares of the biotechnology company’s stock worth $37,198,000 after buying an additional 34,532 shares in the last quarter. Nicholas Investment Partners LP acquired a new position in shares of Cambrex Corporation during the fourth quarter worth $1,175,000. Finally, Columbia Wanger Asset Management LLC boosted its position in Cambrex Corporation by 41.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 269,795 shares of the biotechnology company’s stock worth $14,555,000 after buying an additional 79,009 shares during the last quarter. Institutional investors and hedge funds own 98.28% of the company’s stock.
Shares of Cambrex Corporation (NYSE CBM) traded up 0.51% during midday trading on Tuesday, reaching $59.40. The company had a trading volume of 256,101 shares. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 22.61 and a beta of 2.42. The stock has a 50-day moving average of $55.03 and a 200 day moving average of $54.22.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.17. The company had revenue of $105.01 million during the quarter, compared to analyst estimates of $99.05 million. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.50 earnings per share. On average, analysts anticipate that Cambrex Corporation will post $3.02 earnings per share for the current year.
CBM has been the subject of a number of research reports. Zacks Investment Research upgraded Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a report on Thursday, May 11th. BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Finally, ValuEngine cut Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $64.00.
In related news, VP Samantha Hanley sold 14,000 shares of Cambrex Corporation stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $57.56, for a total value of $805,840.00. Following the completion of the transaction, the vice president now owns 1,500 shares in the company, valued at $86,340. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $54.19, for a total value of $650,280.00. Following the completion of the transaction, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,656 shares of company stock valued at $3,965,183. 2.48% of the stock is currently owned by company insiders.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.